{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T16:55:01Z","timestamp":1791478501702,"version":"4.3.4"},"reference-count":183,"publisher":"Harborside Press, LLC","issue":"7","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2026,7]]},"abstract":"<jats:p>The NCCN Clinical Practice Guidelines for Breast Cancer include recommendations for clinical management of patients with carcinoma in situ, invasive breast cancer, Paget\u2019s disease, Phyllodes tumor, inflammatory breast cancer, and management of breast cancer during pregnancy. The panel convenes annually to update recommendations based on a review of recently published clinical trials. This selection from the NCCN Guidelines for Breast Cancer focuses on the recommendations for the management of recurrent or stage IV (M1) metastatic breast cancer. It summarizes the treatment strategies stratified by tumor biology, including hormone receptor status and HER2 expression, as well as clinical factors such as prior therapy and disease-free interval. Throughout all treatment lines, supportive care, quality of life preservation, toxicity minimization, and clinical trial participation are emphasized as integral components of patient care.<\/jats:p>","DOI":"10.6004\/jnccn.2026.0033","type":"journal-article","created":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:30Z","timestamp":1783600890000},"source":"Crossref","is-referenced-by-count":6,"title":["Breast Cancer, Version 4.2026, NCCN Clinical Practice Guidelines In Oncology"],"prefix":"10.6004","volume":"24","author":[{"given":"William J.","family":"Gradishar","sequence":"first","affiliation":[{"name":"Robert H. Lurie Comprehensive Cancer Center of Northwestern University"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Meena S.","family":"Moran","sequence":"additional","affiliation":[{"name":"Yale Cancer Center\/Smilow Cancer Hospital"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jame","family":"Abraham","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vandana","family":"Abramson","sequence":"additional","affiliation":[{"name":"Vanderbilt-Ingram Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rebecca","family":"Aft","sequence":"additional","affiliation":[{"name":"Siteman Cancer Center at Barnes-Jewish Hospital and WashU Medicine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Doreen","family":"Agnese","sequence":"additional","affiliation":[{"name":"The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kimberly H.","family":"Allison","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bethany","family":"Anderson","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janet","family":"Bailey","sequence":"additional","affiliation":[{"name":"University of Michigan Rogel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Harold J.","family":"Burstein","sequence":"additional","affiliation":[{"name":"Dana-Farber\/Brigham and Women\u2019s Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nan","family":"Chen","sequence":"additional","affiliation":[{"name":"The UChicago Medicine Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Helen","family":"Chew","sequence":"additional","affiliation":[{"name":"UC Davis Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chau","family":"Dang","sequence":"additional","affiliation":[{"name":"Memorial Sloan Kettering Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony D.","family":"Elias","sequence":"additional","affiliation":[{"name":"University of Colorado Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon H.","family":"Giordano","sequence":"additional","affiliation":[{"name":"The University of Texas MD Anderson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew P.","family":"Goetz","sequence":"additional","affiliation":[{"name":"Mayo Clinic Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rachel C.","family":"Jankowitz","sequence":"additional","affiliation":[{"name":"Abramson Cancer Center at the University of Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara H.","family":"Javid","sequence":"additional","affiliation":[{"name":"Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A. Marilyn","family":"Leitch","sequence":"additional","affiliation":[{"name":"UT Southwestern Simmons Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janice","family":"Lyons","sequence":"additional","affiliation":[{"name":"Case Comprehensive Cancer Center\/University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susie","family":"McCloskey","sequence":"additional","affiliation":[{"name":"UCLA Jonsson Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melissa","family":"McShane","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sameer A.","family":"Patel","sequence":"additional","affiliation":[{"name":"Fox Chase Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura H.","family":"Rosenberger","sequence":"additional","affiliation":[{"name":"Duke Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hope S.","family":"Rugo","sequence":"additional","affiliation":[{"name":"City of Hope National Medical Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cesar A.","family":"Santa-Maria","sequence":"additional","affiliation":[{"name":"Johns Hopkins Kimmel Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bryan P.","family":"Schneider","sequence":"additional","affiliation":[{"name":"Indiana University Melvin and Bren Simon Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mary Lou","family":"Smith","sequence":"additional","affiliation":[{"name":"Research Advocacy Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hatem","family":"Soliman","sequence":"additional","affiliation":[{"name":"Moffitt Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Corey","family":"Speers","sequence":"additional","affiliation":[{"name":"O\u2019Neal Comprehensive Cancer Center at UAB"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Melinda L.","family":"Telli","sequence":"additional","affiliation":[{"name":"Stanford Cancer Institute"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mei","family":"Wei","sequence":"additional","affiliation":[{"name":"Huntsman Cancer Institute at the University of Utah"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kari B.","family":"Wisinski","sequence":"additional","affiliation":[{"name":"University of Wisconsin Carbone Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amulya","family":"Yellala","sequence":"additional","affiliation":[{"name":"Fred & Pamela Buffett Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kay T.","family":"Yeung","sequence":"additional","affiliation":[{"name":"UC San Diego Moores Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jessica S.","family":"Young","sequence":"additional","affiliation":[{"name":"Roswell Park Comprehensive Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ryan","family":"Schonfeld","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rashmi","family":"Kumar","sequence":"additional","affiliation":[{"name":"National Comprehensive Cancer Network"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"4047","reference":[{"key":"B1","series-title":"Eur J Cancer","first-page":"1704","article-title":"Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer","volume":"40","author":"Diel IJ","year":"2004","unstructured":"Diel IJ, Body JJ, Lichinitser MR,  Improved quality of life after long-term treatment with the bisphosphonate ibandronate in patients with metastatic bone disease due to breast cancer. Eur J Cancer 2004;40:1704\u20131712."},{"key":"B2","series-title":"J Clin Oncol","first-page":"2038","article-title":"Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group","volume":"16","author":"Hortobagyi GN","year":"1998","unstructured":"Hortobagyi GN, Theriault RL, Lipton A,  Long-term prevention of skeletal complications of metastatic breast cancer with pamidronate. Protocol 19 Aredia Breast Cancer Study Group. J Clin Oncol 1998;16:2038\u20132044."},{"key":"B3","series-title":"N Engl J Med","first-page":"1785","article-title":"Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group","volume":"335","author":"Hortobagyi GN","year":"1996","unstructured":"Hortobagyi GN, Theriault RL, Porter L,  Efficacy of pamidronate in reducing skeletal complications in patients with breast cancer and lytic bone metastases. Protocol 19 Aredia Breast Cancer Study Group. N Engl J Med 1996;335:1785\u20131791."},{"key":"B4","series-title":"Cancer","first-page":"1082","article-title":"Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials","volume":"88","author":"Lipton A","year":"2000","unstructured":"Lipton A, Theriault RL, Hortobagyi GN,  Pamidronate prevents skeletal complications and is effective palliative treatment in women with breast carcinoma and osteolytic bone metastases: long term follow-up of two randomized, placebo-controlled trials. Cancer 2000;88:1082\u20131090."},{"key":"B5","series-title":"Clin Drug Investig","first-page":"43","article-title":"Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience","volume":"26","author":"McLachlan SA","year":"2006","unstructured":"McLachlan SA, Cameron D, Murray R,  Safety of oral ibandronate in the treatment of bone metastases from breast cancer: long-term follow-up experience. Clin Drug Investig 2006;26:43\u201348."},{"key":"B6","series-title":"Clin Drug Investig","first-page":"315","article-title":"Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial","volume":"26","author":"Pecherstorfer M","year":"2006","unstructured":"Pecherstorfer M, Rivkin S, Body JJ,  Long-term safety of intravenous ibandronic acid for up to 4 years in metastatic breast cancer: an open-label trial. Clin Drug Investig 2006;26:315\u2013322."},{"key":"B7","series-title":"Cancer","first-page":"36","article-title":"Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion","volume":"100","author":"Rosen LS","year":"2004","unstructured":"Rosen LS, Gordon DH, Dugan W,  Zoledronic acid is superior to pamidronate for the treatment of bone metastases in breast carcinoma patients with at least one osteolytic lesion. Cancer 2004;100:36\u201343."},{"key":"B8","series-title":"J Clin Oncol","first-page":"846","article-title":"Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group","volume":"17","author":"Theriault RL","year":"1999","unstructured":"Theriault RL, Lipton A, Hortobagyi GN,  Pamidronate reduces skeletal morbidity in women with advanced breast cancer and lytic bone lesions: a randomized, placebo-controlled trial. Protocol 18 Aredia Breast Cancer Study Group. J Clin Oncol 1999;17:846\u2013854."},{"key":"B9","series-title":"Lancet Oncol","first-page":"663","article-title":"Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial","volume":"14","author":"Amadori D","year":"2013","unstructured":"Amadori D, Aglietta M, Alessi B,  Efficacy and safety of 12-weekly versus 4-weekly zoledronic acid for prolonged treatment of patients with bone metastases from breast cancer (ZOOM): a phase 3, open-label, randomised, non-inferiority trial. Lancet Oncol 2013;14:663\u2013670."},{"key":"B10","series-title":"JAMA","first-page":"48","article-title":"Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial","volume":"317","author":"Himelstein AL","year":"2017","unstructured":"Himelstein AL, Foster JC, Khatcheressian JL,  Effect of longer-interval vs standard dosing of zoledronic acid on skeletal events in patients with bone metastases: a randomized clinical trial. JAMA 2017;317:48\u201358."},{"key":"B11","series-title":"JAMA Oncol","first-page":"906","article-title":"Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial","volume":"3","author":"Hortobagyi GN","year":"2017","unstructured":"Hortobagyi GN, Van Poznak C, Harker WG,  Continued treatment effect of zoledronic acid dosing every 12 vs 4 weeks in women with breast cancer metastatic to bone: the OPTIMIZE-2 randomized clinical trial. JAMA Oncol 2017;3:906\u2013912."},{"key":"B12","article-title":"Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial","author":"Hortobagyi GN","unstructured":"Hortobagyi GN, Lipton A, Chew HK,  Efficacy and safety of continued zoledronic acid every 4 weeks versus every 12 weeks in women with bone metastases from breast cancer: results of the OPTIMIZE-2 trial. Presented at 2014 ASCO Annual Meeting II; May 30\u2013June 3, 2014; Chicago, Illinois. Abstract LBA9500."},{"key":"B13","series-title":"Cancer","first-page":"1735","article-title":"Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial","volume":"98","author":"Rosen LS","year":"2003","unstructured":"Rosen LS, Gordon D, Kaminski M,  Long-term efficacy and safety of zoledronic acid compared with pamidronate disodium in the treatment of skeletal complications in patients with advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98:1735\u20131744."},{"key":"B14","series-title":"Clin Adv Hematol Oncol","first-page":"159","article-title":"Denosumab findings in metastatic breast cancer","volume":"8","author":"Stopeck A","year":"2010","unstructured":"Stopeck A. Denosumab findings in metastatic breast cancer. Clin Adv Hematol Oncol 2010;8:159\u2013160."},{"key":"B15","series-title":"Ann Intern Med","first-page":"753","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo SB","year":"2006","unstructured":"Woo SB, Hellstein JW, Kalmar JR. Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws. Ann Intern Med 2006;144:753\u2013761."},{"key":"B16","series-title":"Ann Oncol","first-page":"1623","article-title":"5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5)","volume":"31","author":"Cardoso F","year":"2020","unstructured":"Cardoso F, Paluch-Shimon S, Senkus E,  5th ESO-ESMO international consensus guidelines for advanced breast cancer (ABC 5). Ann Oncol 2020;31:1623\u20131649."},{"key":"B17","series-title":"Breast","first-page":"103756","article-title":"6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7)","volume":"76","author":"Cardoso F","year":"2024","unstructured":"Cardoso F, Paluch-Shimon S, Schumacher-Wulf E,  6th and 7th International consensus guidelines for the management of advanced breast cancer (ABC guidelines 6 and 7). Breast 2024;76:103756."},{"key":"B18","series-title":"J Clin Oncol","first-page":"2812","article-title":"Final results of RIGHT Choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer","volume":"42","author":"Lu YS","year":"2024","unstructured":"Lu YS, Mahidin EIBM, Azim H,  Final results of RIGHT Choice: ribociclib plus endocrine therapy versus combination chemotherapy in premenopausal women with clinically aggressive hormone receptor\u2013positive\/human epidermal growth factor receptor 2\u2013negative advanced breast cancer. J Clin Oncol 2024;42:2812\u20132821."},{"key":"B19","series-title":"Clin Cancer Res","first-page":"LB1","article-title":"Primary results of the randomised Phase. trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study","volume":"31(Suppl)","author":"Loibl S","year":"2025","unstructured":"Loibl S, Thill M, Rey J,  Primary results of the randomised Phase. trial comparing first-line ET plus palbociclib vs standard mono-chemotherapy in women with high risk HER2-\/HR+ metastatic breast cancer and indication for chemotherapy - PADMA study. Clin Cancer Res 2025;31(Suppl):LB1\u201303."},{"key":"B20","article-title":"Abstract RF7-06: Primary results of Ambre, a randomized phase 3 comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+\/her2- advanced breast cancer (abc) with high visceral tumor burden","author":"Dieras V","unstructured":"Dieras V, Bidard FC, Roca L,  Abstract RF7-06: Primary results of Ambre, a randomized phase 3 comparing mono-chemotherapy (ct) vs abemaciclib + endocrine therapy (et) in hr+\/her2- advanced breast cancer (abc) with high visceral tumor burden. Presented at 2025 San Antonio Breast Cancer Symposium; December 9\u201312, 2025; San Antonio, Texas. Abstract RF7-06."},{"key":"B21","series-title":"Ann Oncol","first-page":"1541","article-title":"Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer","volume":"29","author":"Hortobagyi GN","year":"2018","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA,  Updated results from MONALEESA-2, a phase III trial of first-line ribociclib plus letrozole versus placebo plus letrozole in hormone receptor-positive, HER2-negative advanced breast cancer. Ann Oncol 2018;29:1541\u20131547."},{"key":"B22","article-title":"Prescribing information for KISQALI\u00ae (ribociclib) tablets, for oral use. 2022","unstructured":"Prescribing information for KISQALI\u00ae (ribociclib) tablets, for oral use. 2022. Accessed May 22, 2026. Available at: https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2022\/209092s013,209935s021lbl.pdf"},{"key":"B23","series-title":"Lancet Oncol","first-page":"904","article-title":"Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial","volume":"19","author":"Tripathy D","year":"2018","unstructured":"Tripathy D, Im SA, Colleoni M,  Ribociclib plus endocrine therapy for premenopausal women with hormone-receptor-positive, advanced breast cancer (MONALEESA-7): a randomised phase 3 trial. Lancet Oncol 2018;19:904\u2013915."},{"key":"B24","series-title":"N Engl J Med","first-page":"942","article-title":"Overall survival with ribociclib plus letrozole in advanced breast cancer","volume":"386","author":"Hortobagyi GN","year":"2022","unstructured":"Hortobagyi GN, Stemmer SM, Burris HA,  Overall survival with ribociclib plus letrozole in advanced breast cancer. N Engl J Med 2022;386:942\u2013950."},{"key":"B25","series-title":"Clin Cancer Res","first-page":"851","article-title":"Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial","volume":"28","author":"Lu YS","year":"2022","unstructured":"Lu YS, Im SA, Colleoni M,  Updated overall survival of ribociclib plus endocrine therapy versus endocrine therapy alone in pre- and perimenopausal patients with HR+\/HER2- advanced breast cancer in MONALEESA-7: a phase III randomized clinical trial. Clin Cancer Res 2022;28:851\u2013859."},{"key":"B26","series-title":"J Clin Oncol","first-page":"3638","article-title":"MONARCH 3: abemaciclib as initial therapy for advanced breast cancer","volume":"35","author":"Goetz MP","year":"2017","unstructured":"Goetz MP, Toi M, Campone M,  MONARCH 3: abemaciclib as initial therapy for advanced breast cancer. J Clin Oncol 2017;35:3638\u20133646."},{"key":"B27","series-title":"Ann Oncol","first-page":"718","article-title":"Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3","volume":"35","author":"Goetz MP","year":"2024","unstructured":"Goetz MP, Toi M, Huober J,  Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: final overall survival results of MONARCH 3. Ann Oncol 2024;35:718\u2013727."},{"key":"B28","series-title":"N Engl J Med","first-page":"1925","article-title":"Palbociclib and letrozole in advanced breast cancer","volume":"375","author":"Finn RS","year":"2016","unstructured":"Finn RS, Martin M, Rugo HS,  Palbociclib and letrozole in advanced breast cancer. N Engl J Med 2016;375:1925\u20131936."},{"key":"B29","series-title":"J Clin Oncol","first-page":"994","article-title":"Overall survival with palbociclib plus letrozole in advanced breast cancer","volume":"42","author":"Slamon DJ","year":"2024","unstructured":"Slamon DJ, Di\u00e9ras V, Rugo HS,  Overall survival with palbociclib plus letrozole in advanced breast cancer. J Clin Oncol 2024;42:994\u20131000."},{"key":"B30","series-title":"Clin Cancer Res","first-page":"4760","article-title":"FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer","volume":"21","author":"Beaver JA","year":"2015","unstructured":"Beaver JA, Amiri-Kordestani L, Charlab R,  FDA approval: palbociclib for the treatment of postmenopausal patients with estrogen receptor-positive, HER2-negative metastatic breast cancer. Clin Cancer Res 2015;21:4760\u20134766."},{"key":"B31","series-title":"Nature","first-page":"474","article-title":"Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer","volume":"636","author":"Sonke GS","year":"2024","unstructured":"Sonke GS, van Ommen-Nijhof A, Wortelboer N,  Early versus deferred use of CDK4\/6 inhibitors in advanced breast cancer. Nature 2024;636:474\u2013480."},{"key":"B32","series-title":"N Engl J Med","first-page":"1584","article-title":"Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer","volume":"391","author":"Turner NC","year":"2024","unstructured":"Turner NC, Im SA, Saura C,  Inavolisib-based therapy in PIK3CA-mutated advanced breast cancer. N Engl J Med 2024;391:1584\u20131596."},{"key":"B33","series-title":"N Engl J Med","first-page":"151","article-title":"Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer","volume":"393","author":"Jhaveri KL","year":"2025","unstructured":"Jhaveri KL, Im SA, Saura C,  Overall survival with inavolisib in PIK3CA-mutated advanced breast cancer. N Engl J Med 2025;393:151\u2013161."},{"key":"B34","series-title":"J Clin Oncol","first-page":"2465","article-title":"Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3","volume":"36","author":"Slamon DJ","year":"2018","unstructured":"Slamon DJ, Neven P, Chia S,  Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3. J Clin Oncol 2018;36:2465\u20132472. :Jco2018789909."},{"key":"B35","series-title":"N Engl J Med","first-page":"514","article-title":"Overall survival with ribociclib plus fulvestrant in advanced breast cancer","volume":"382","author":"Slamon DJ","year":"2020","unstructured":"Slamon DJ, Neven P, Chia S,  Overall survival with ribociclib plus fulvestrant in advanced breast cancer. N Engl J Med 2020;382:514\u2013524."},{"key":"B36","series-title":"J Clin Oncol","first-page":"2875","article-title":"MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy","volume":"35","author":"Sledge GW","year":"2017","unstructured":"Sledge GW, Toi M, Neven P,  MONARCH 2: Abemaciclib in combination with fulvestrant in women with HR+\/HER2- advanced breast cancer who had progressed while receiving endocrine therapy. J Clin Oncol 2017;35:2875\u20132884."},{"key":"B37","series-title":"JAMA Oncol","first-page":"116","article-title":"The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial","volume":"6","author":"Sledge GW","year":"2020","unstructured":"Sledge GW, Toi M, Neven P,  The effect of abemaciclib plus fulvestrant on overall survival in hormone receptor-positive, ERBB2-negative breast cancer that progressed on endocrine therapy-MONARCH 2: a randomized clinical trial. JAMA Oncol 2020;6:116\u2013124."},{"key":"B38","series-title":"Lancet Oncol","first-page":"425","article-title":"Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial","volume":"17","author":"Cristofanilli M","year":"2016","unstructured":"Cristofanilli M, Turner NC, Bondarenko I,  Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial. Lancet Oncol 2016;17:425\u2013439."},{"key":"B39","series-title":"J Clin Oncol","first-page":"1101","article-title":"Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial","volume":"43","author":"Kalinsky K","year":"2025","unstructured":"Kalinsky K, Bianchini G, Hamilton E,  Abemaciclib plus fulvestrant in advanced breast cancer after progression on CDK4\/6 inhibition: results from the phase III postMONARCH trial. J Clin Oncol 2025;43:1101\u20131112."},{"key":"B40","series-title":"J Clin Oncol","first-page":"4004","article-title":"Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial","volume":"41","author":"Kalinsky K","year":"2023","unstructured":"Kalinsky K, Accordino MK, Chiuzan C,  Randomized phase II trial of endocrine therapy with or without ribociclib after progression on cyclin-dependent kinase 4\/6 inhibition in hormone receptor-positive, human epidermal growth factor receptor 2-negative metastatic breast cancer: MAINTAIN trial. J Clin Oncol 2023;41:4004\u20134013."},{"key":"B41","series-title":"N Engl J Med","first-page":"1929","article-title":"Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer","volume":"380","author":"Andre F","year":"2019","unstructured":"Andre F, Ciruelos E, Rubovszky G,  Alpelisib for PIK3CA-mutated, hormone receptor-positive advanced breast cancer. N Engl J Med 2019;380:1929\u20131940."},{"key":"B42","series-title":"N Engl J Med","first-page":"2058","article-title":"Capivasertib in hormone receptor-positive advanced breast cancer","volume":"388","author":"Turner NC","year":"2023","unstructured":"Turner NC, Oliveira M, Howell SJ,  Capivasertib in hormone receptor-positive advanced breast cancer. N Engl J Med 2023;388:2058\u20132070."},{"key":"B43","series-title":"Cancer Res","first-page":"Abstract S1","article-title":"TAMRAD: a GINECO randomized phase. trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI)","volume":"70","author":"Bachelot T","year":"2010","unstructured":"Bachelot T, Bourgier C, Cropet C,  TAMRAD: a GINECO randomized phase. trial of everolimus in combination with tamoxifen versus tamoxifen alone in patients (pts) with hormone-receptor positive, HER2 negative metastatic breast cancer (MBC) with prior exposure to aromatase inhibitors (AI). Cancer Res 2010;70(Suppl):Abstract S1\u20136."},{"key":"B44","series-title":"Breast Cancer Res Treat","first-page":"6091","article-title":"Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer","volume":"100","author":"Chow L","year":"2006","unstructured":"Chow L, Sun Y, Jassem J,  Phase 3 study of temsirolimus with letrozole or letrozole alone in postmenopausal women with locally advanced or metastatic breast cancer. Breast Cancer Res Treat 2006;100(Suppl 1):6091."},{"key":"B45","series-title":"Adv Ther","first-page":"870","article-title":"Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis","volume":"30","author":"Yardley DA","year":"2013","unstructured":"Yardley DA, Noguchi S, Pritchard KI,  Everolimus plus exemestane in postmenopausal patients with HR(+) breast cancer: BOLERO-2 final progression-free survival analysis. Adv Ther 2013;30:870\u2013884."},{"key":"B46","series-title":"N Engl J Med","first-page":"520","article-title":"Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer","volume":"366","author":"Baselga J","year":"2012","unstructured":"Baselga J, Campone M, Piccart M,  Everolimus in postmenopausal hormone-receptor-positive advanced breast cancer. N Engl J Med 2012;366:520\u2013529."},{"key":"B47","series-title":"Clin Breast Cancer","first-page":"421","article-title":"Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2","volume":"13","author":"Pritchard KI","year":"2013","unstructured":"Pritchard KI, Burris HA, Ito Y,  Safety and efficacy of everolimus with exemestane vs. exemestane alone in elderly patients with HER2-negative, hormone receptor-positive breast cancer in BOLERO-2. Clin Breast Cancer 2013;13:421\u2013432.e8."},{"key":"B48","series-title":"J Clin Oncol","first-page":"2961","article-title":"Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer","volume":"34","author":"Fribbens C","year":"2016","unstructured":"Fribbens C, O\u2019Leary B, Kilburn L,  Plasma ESR1 mutations and the treatment of estrogen receptor-positive advanced breast cancer. J Clin Oncol 2016;34:2961\u20132968."},{"key":"B49","series-title":"JAMA Oncol","first-page":"1310","article-title":"Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial","volume":"2","author":"Chandarlapaty S","year":"2016","unstructured":"Chandarlapaty S, Chen D, He W,  Prevalence of ESR1 mutations in cell-free DNA and outcomes in metastatic breast cancer: a secondary analysis of the BOLERO-2 clinical trial. JAMA Oncol 2016;2:1310\u20131315."},{"key":"B50","series-title":"Oncologist","first-page":"S7","article-title":"Elacestrant improves progression-free survival after endocrine therapy for estrogen receptor-positive metastatic breast cancer","volume":"27","author":"Jacobson A","year":"2022","unstructured":"Jacobson A. Elacestrant improves progression-free survival after endocrine therapy for estrogen receptor-positive metastatic breast cancer. Oncologist 2022;27:S7\u20138."},{"key":"B51","series-title":"Clin Cancer Res","first-page":"4299","article-title":"Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups","volume":"30","author":"Bardia A","year":"2024","unstructured":"Bardia A, Cortes J, Bidard FC,  Elacestrant in ER+, HER2- metastatic breast cancer with ESR1-mutated tumors: subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4\/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30:4299\u20134309."},{"key":"B52","series-title":"N Engl J Med","first-page":"1189","article-title":"Imlunestrant with or without abemaciclib in advanced breast cancer","volume":"392","author":"Jhaveri KL","year":"2025","unstructured":"Jhaveri KL, Neven P, Casalnuovo ML,  Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392:1189\u20131202."},{"key":"B53","series-title":"J Clin Oncol","first-page":"1919","article-title":"FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer","volume":"30","author":"Bergh J","year":"2012","unstructured":"Bergh J, Jonsson PE, Lidbrink EK,  FACT: an open-label randomized phase III study of fulvestrant and anastrozole in combination compared with anastrozole alone as first-line therapy for patients with receptor-positive postmenopausal breast cancer. J Clin Oncol 2012;30:1919\u20131925."},{"key":"B54","series-title":"Lancet Oncol","first-page":"989","article-title":"Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial","volume":"14","author":"Johnston SR","year":"2013","unstructured":"Johnston SR, Kilburn LS, Ellis P,  Fulvestrant plus anastrozole or placebo versus exemestane alone after progression on non-steroidal aromatase inhibitors in postmenopausal patients with hormone-receptor-positive locally advanced or metastatic breast cancer (SoFEA): a composite, multicentre, phase 3 randomised trial. Lancet Oncol 2013;14:989\u2013998."},{"key":"B55","series-title":"N Engl J Med","first-page":"435","article-title":"Combination anastrozole and fulvestrant in metastatic breast cancer","volume":"367","author":"Mehta RS","year":"2012","unstructured":"Mehta RS, Barlow WE, Albain KS,  Combination anastrozole and fulvestrant in metastatic breast cancer. N Engl J Med 2012;367:435\u2013444."},{"key":"B56","series-title":"N Engl J Med","first-page":"1226","article-title":"Overall survival with fulvestrant plus anastrozole in metastatic breast cancer","volume":"380","author":"Mehta RS","year":"2019","unstructured":"Mehta RS, Barlow WE, Albain KS,  Overall survival with fulvestrant plus anastrozole in metastatic breast cancer. N Engl J Med 2019;380:1226\u20131234."},{"key":"B57","series-title":"Clin Breast Cancer","first-page":"39","article-title":"A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases","volume":"9","author":"Campos SM","year":"2009","unstructured":"Campos SM, Guastalla JP, Subar M,  A comparative study of exemestane versus anastrozole in patients with postmenopausal breast cancer with visceral metastases. Clin Breast Cancer 2009;9:39\u201344."},{"key":"B58","series-title":"Breast Cancer Res Treat","first-page":"741","article-title":"Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability","volume":"125","author":"Dixon JM","year":"2011","unstructured":"Dixon JM, Renshaw L, Langridge C,  Anastrozole and letrozole: an investigation and comparison of quality of life and tolerability. Breast Cancer Res Treat 2011;125:741\u2013749."},{"key":"B59","series-title":"Eur J Cancer","first-page":"2318","article-title":"An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole","volume":"39","author":"Rose C","year":"2003","unstructured":"Rose C, Vtoraya O, Pluzanska A,  An open randomised trial of second-line endocrine therapy in advanced breast cancer. comparison of the aromatase inhibitors letrozole and anastrozole. Eur J Cancer 2003;39:2318\u20132327."},{"key":"B60","series-title":"J Clin Oncol","first-page":"1283","article-title":"Tamoxifen in premenopausal patients with metastatic breast cancer: a review","volume":"9","author":"Sunderland MC","year":"1991","unstructured":"Sunderland MC, Osborne CK. Tamoxifen in premenopausal patients with metastatic breast cancer: a review. J Clin Oncol 1991;9:1283\u20131297."},{"key":"B61","series-title":"J Clin Oncol","first-page":"3748","article-title":"Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study","volume":"18","author":"Bonneterre J","year":"2000","unstructured":"Bonneterre J, Thurlimann B, Robertson JF,  Anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in 668 postmenopausal women: results of the Tamoxifen or Arimidex Randomized Group Efficacy and Tolerability study. J Clin Oncol 2000;18:3748\u20133757."},{"key":"B62","series-title":"J Clin Oncol","first-page":"3758","article-title":"Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group","volume":"18","author":"Nabholtz JM","year":"2000","unstructured":"Nabholtz JM, Buzdar A, Pollak M,  Anastrozole is superior to tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women: results of a North American multicenter randomized trial. Arimidex Study Group. J Clin Oncol 2000;18:3758\u20133767."},{"key":"B63","series-title":"J Clin Oncol","first-page":"4883","article-title":"Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group","volume":"26","author":"Paridaens RJ","year":"2008","unstructured":"Paridaens RJ, Dirix LY, Beex LV,  Phase III study comparing exemestane with tamoxifen as first-line hormonal treatment of metastatic breast cancer in postmenopausal women: the European Organisation for Research and Treatment of Cancer Breast Cancer Cooperative Group. J Clin Oncol 2008;26:4883\u20134890."},{"key":"B64","series-title":"Eur J Cancer","first-page":"S84","article-title":"Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women","volume":"36","author":"Vergote I","year":"2000","unstructured":"Vergote I, Bonneterre J, Thurlimann B,  Randomised study of anastrozole versus tamoxifen as first-line therapy for advanced breast cancer in postmenopausal women. Eur J Cancer 2000;36(Suppl 4):S84\u201385."},{"key":"B65","series-title":"J Natl Cancer Inst","first-page":"1285","article-title":"Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis","volume":"98","author":"Mauri D","year":"2006","unstructured":"Mauri D, Pavlidis N, Polyzos NP, Ioannidis JP. Survival with aromatase inhibitors and inactivators versus standard hormonal therapy in advanced breast cancer: meta-analysis. J Natl Cancer Inst 2006;98:1285\u20131291."},{"key":"B66","series-title":"Eur J Cancer","first-page":"2310","article-title":"Efficacy of tamoxifen following anastrozole (\u2018Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women","volume":"39","author":"Thurlimann B","year":"2003","unstructured":"Thurlimann B, Robertson JF, Nabholtz JM,  Efficacy of tamoxifen following anastrozole (\u2018Arimidex') compared with anastrozole following tamoxifen as first-line treatment for advanced breast cancer in postmenopausal women. Eur J Cancer 2003;39:2310\u20132317."},{"key":"B67","series-title":"Lancet","first-page":"2997","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial","volume":"388","author":"Robertson JFR","year":"2016","unstructured":"Robertson JFR, Bondarenko IM, Trishkina E,  Fulvestrant 500 mg versus anastrozole 1 mg for hormone receptor-positive advanced breast cancer (FALCON): an international, randomised, double-blind, phase 3 trial. Lancet 2016;388:2997\u20133005."},{"key":"B68","series-title":"J Clin Oncol","first-page":"3396","article-title":"Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment","volume":"20","author":"Howell A","year":"2002","unstructured":"Howell A, Robertson JFR, Quaresma Albano J,  Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment. J Clin Oncol 2002;20:3396\u20133403."},{"key":"B69","series-title":"J Clin Oncol","first-page":"3386","article-title":"Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial","volume":"20","author":"Osborne CK","year":"2002","unstructured":"Osborne CK, Pippen J, Jones SE,  Double-blind, randomized trial comparing the efficacy and tolerability of fulvestrant versus anastrozole in postmenopausal women with advanced breast cancer progressing on prior endocrine therapy: results of a North American trial. J Clin Oncol 2002;20:3386\u20133395."},{"key":"B70","series-title":"J Clin Oncol","first-page":"4530","article-title":"Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study","volume":"27","author":"Robertson JF","year":"2009","unstructured":"Robertson JF, Llombart-Cussac A, Rolski J,  Activity of fulvestrant 500 mg versus anastrozole 1 mg as first-line treatment for advanced breast cancer: results from the FIRST study. J Clin Oncol 2009;27:4530\u20134535."},{"key":"B71","series-title":"Breast Cancer Res Treat","first-page":"503","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized \u2018FIRST\u2019 study","volume":"136","author":"Robertson JF","year":"2012","unstructured":"Robertson JF, Lindemann JP, Llombart-Cussac A,  Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: follow-up analysis from the randomized \u2018FIRST\u2019 study. Breast Cancer Res Treat 2012;136:503\u2013511."},{"key":"B72","series-title":"J Clin Oncol","first-page":"3781","article-title":"Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study","volume":"33","author":"Ellis MJ","year":"2015","unstructured":"Ellis MJ, Llombart-Cussac A, Feltl D,  Fulvestrant 500 mg versus anastrozole 1 mg for the first-line treatment of advanced breast cancer: overall survival analysis from the phase II FIRST study. J Clin Oncol 2015;33:3781\u20133787."},{"key":"B73","series-title":"J Clin Oncol","first-page":"1664","article-title":"Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT","volume":"26","author":"Chia S","year":"2008","unstructured":"Chia S, Gradishar W, Mauriac L,  Double-blind, randomized placebo controlled trial of fulvestrant compared with exemestane after prior nonsteroidal aromatase inhibitor therapy in postmenopausal women with hormone receptor-positive, advanced breast cancer: results from EFECT. J Clin Oncol 2008;26:1664\u20131670."},{"key":"B74","series-title":"J Clin Oncol","first-page":"4594","article-title":"Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer","volume":"28","author":"Di Leo A","year":"2010","unstructured":"Di Leo A, Jerusalem G, Petruzelka L,  Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. J Clin Oncol 2010;28:4594\u20134600."},{"key":"B75","series-title":"J Natl Cancer Inst","first-page":"djt337","article-title":"Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial","volume":"106","author":"Di Leo A","year":"2014","unstructured":"Di Leo A, Jerusalem G, Petruzelka L,  Final overall survival: fulvestrant 500 mg vs 250 mg in the randomized CONFIRM trial. J Natl Cancer Inst 2014.;106:djt337."},{"key":"B76","series-title":"J Clin Oncol","first-page":"64","article-title":"Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741","volume":"17","author":"Abrams J","year":"1999","unstructured":"Abrams J, Aisner J, Cirrincione C,  Dose-response trial of megestrol acetate in advanced breast cancer: cancer and leukemia group B phase III study 8741. J Clin Oncol 1999;17:64\u201373."},{"key":"B77","series-title":"Eur J Cancer","first-page":"337","article-title":"A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer","volume":"26","author":"Willemse PH","year":"1990","unstructured":"Willemse PH, van der Ploeg E, Sleijfer DT,  A randomized comparison of megestrol acetate (MA) and medroxyprogesterone acetate (MPA) in patients with advanced breast cancer. Eur J Cancer 1990;26:337\u2013343."},{"key":"B78","series-title":"J Clin Oncol","first-page":"3357","article-title":"Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate","volume":"19","author":"Buzdar A","year":"2001","unstructured":"Buzdar A, Douma J, Davidson N,  Phase III, multicenter, double-blind, randomized study of letrozole, an aromatase inhibitor, for advanced breast cancer versus megestrol acetate. J Clin Oncol 2001;19:3357\u20133366."},{"key":"B79","series-title":"J Clin Oncol","first-page":"2000","article-title":"Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group","volume":"14","author":"Buzdar A","year":"1996","unstructured":"Buzdar A, Jonat W, Howell A,  Anastrozole, a potent and selective aromatase inhibitor, versus megestrol acetate in postmenopausal women with advanced breast cancer: results of overview analysis of two phase III trials. Arimidex Study Group. J Clin Oncol 1996;14:2000\u20132011."},{"key":"B80","series-title":"JAMA","first-page":"774","article-title":"Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study","volume":"302","author":"Ellis MJ","year":"2009","unstructured":"Ellis MJ, Gao F, Dehdashti F,  Lower-dose vs high-dose oral estradiol therapy of hormone receptor-positive, aromatase inhibitor-resistant advanced breast cancer: a phase 2 randomized study. JAMA 2009;302:774\u2013780."},{"key":"B81","series-title":"Clin Cancer Res","first-page":"5218","article-title":"MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer","volume":"23","author":"Dickler MN","year":"2017","unstructured":"Dickler MN, Tolaney SM, Rugo HS,  MONARCH 1, a phase II study of abemaciclib, a CDK4 and CDK6 inhibitor, as a single agent, in patients with refractory HR(+)\/HER2(-) metastatic breast cancer. Clin Cancer Res 2017;23:5218\u20135224."},{"key":"B82","series-title":"N Engl J Med","first-page":"2110","article-title":"Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer","volume":"391","author":"Bardia A","year":"2024","unstructured":"Bardia A, Hu X, Dent R,  Trastuzumab deruxtecan after endocrine therapy in metastatic breast cancer. N Engl J Med 2024;391:2110\u20132122."},{"key":"B83","series-title":"Lancet","first-page":"1423","article-title":"Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial","volume":"402","author":"Rugo HS","year":"2023","unstructured":"Rugo HS, Bardia A, Marm\u00e9 F,  Overall survival with sacituzumab govitecan in hormone receptor-positive and human epidermal growth factor receptor 2-negative metastatic breast cancer (TROPiCS-02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;402:1423\u20131433."},{"key":"B84","series-title":"J Clin Oncol","first-page":"285","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01","volume":"43","author":"Bardia A","year":"2025","unstructured":"Bardia A, Jhaveri K, Im SA,  Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive human epidermal growth factor receptor 2-negative breast cancer: primary results from TROPION-Breast01. J Clin Oncol 2025;43:285\u2013296."},{"key":"B85","series-title":"Ann Oncol","first-page":"663","article-title":"Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study","volume":"37","author":"Pistilli B","year":"2026","unstructured":"Pistilli B, Jhaveri K, Im SA,  Datopotamab deruxtecan versus chemotherapy in previously treated inoperable\/metastatic hormone receptor-positive, HER2-negative breast cancer: final overall survival analysis of the phase III TROPION-Breast01 study. Ann Oncol 2026;37:663\u2013674."},{"key":"B86","series-title":"N Engl J Med","first-page":"109","article-title":"Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer","volume":"366","author":"Baselga J","year":"2012","unstructured":"Baselga J, Cortes J, Kim SB,  Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. N Engl J Med 2012;366:109\u2013119."},{"key":"B87","series-title":"Cancer Res","first-page":"P5\u201318\u201326","article-title":"Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC)","volume":"72","author":"Swain S","unstructured":"Swain S, Kim S-B, Cortes J,  Confirmatory overall survival (OS) analysis of CLEOPATRA: a randomized, double-blind, placebo-controlled Phase III study with pertuzumab (P), trastuzumab (T), and docetaxel (D) in patients (pts) with HER2-positive first-line (1L) metastatic breast cancer (MBC). Cancer Res 2012;72(Suppl):P5\u201318\u201326."},{"key":"B88","series-title":"J Clin Oncol","first-page":"Abstract 533","article-title":"Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study","volume":"30","author":"Ewer M","year":"2012","unstructured":"Ewer M, Baselga J, Clark E,  Cardiac tolerability of pertuzumab plus trastuzumab plus docetaxel in patients with HER2-positive metastatic breast cancer in the CLEOPATRA study. J Clin Oncol 2012;30(Suppl):Abstract 533."},{"key":"B89","series-title":"J Clin Oncol","first-page":"Abstract 598","article-title":"Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer","volume":"30","author":"Cort\u00e9s J","year":"2012","unstructured":"Cort\u00e9s J, Baselga J, Im Y,  Quality of life assessment in CLEOPATRA, a phase III study combining pertuzumab with trastuzumab and docetaxel in metastatic breast cancer. J Clin Oncol 2012;30(Suppl):Abstract 598."},{"key":"B90","series-title":"Ann Oncol","first-page":"766","article-title":"Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE)","volume":"30","author":"Bachelot T","year":"2019","unstructured":"Bachelot T, Ciruelos E, Schneeweiss A,  Preliminary safety and efficacy of first-line pertuzumab combined with trastuzumab and taxane therapy for HER2-positive locally recurrent or metastatic breast cancer (PERUSE). Ann Oncol 2019;30:766\u2013773."},{"key":"B91","series-title":"Cancer Res","first-page":"Abstract 606","article-title":"Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer (MBC)","volume":"72","author":"Datko FM","year":"2012","unstructured":"Datko FM, D\u2019Andrea G, Dickler MN,  Phase II study of pertuzumab, trastuzumab, and weekly paclitaxel in patients with metastatic HER2-overexpressing metastatic breast cancer (MBC). Cancer Res 2012;72(Suppl):Abstract 606."},{"key":"B92","series-title":"J Clin Oncol","first-page":"Asbtract TPS653","article-title":"A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET)","volume":"30","author":"Perez E","year":"2012","unstructured":"Perez E, Lopez-Vega J, Mastro L,  A combination of pertuzumab, trastuzumab, and vinorelbine for first-line treatment of patients with HER2-positive metastatic breast cancer: an open-label, two-cohort, phase II study (VELVET). J Clin Oncol 2012;30(Suppl):Asbtract TPS653."},{"key":"B93","series-title":"N Engl J Med","first-page":"451","article-title":"Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer","volume":"394","author":"Metzger O","year":"2026","unstructured":"Metzger O, Mandrekar S, Goel S,  Palbociclib for hormone-receptor-positive, HER2-positive advanced breast cancer. N Engl J Med 2026;394:451\u2013462."},{"key":"B94","series-title":"N Engl J Med","first-page":"551","article-title":"Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer","volume":"394","author":"Tolaney SM","year":"2026","unstructured":"Tolaney SM, Jiang Z, Zhang Q,  Trastuzumab deruxtecan plus pertuzumab for HER2-positive metastatic breast cancer. N Engl J Med 2026;394:551\u2013562."},{"key":"B95","series-title":"Lancet","first-page":"1773","article-title":"Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial","volume":"401","author":"Andr\u00e9 F","year":"2023","unstructured":"Andr\u00e9 F, Hee Park Y, Kim SB,  Trastuzumab deruxtecan versus treatment of physician\u2019s choice in patients with HER2-positive metastatic breast cancer (DESTINY-Breast02): a randomised, open-label, multicentre, phase 3 trial. Lancet 2023;401:1773\u20131785."},{"key":"B96","series-title":"Nat Med","first-page":"2208","article-title":"Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial","volume":"30","author":"Cort\u00e9s J","year":"2024","unstructured":"Cort\u00e9s J, Hurvitz SA, Im SA,  Trastuzumab deruxtecan versus trastuzumab emtansine in HER2-positive metastatic breast cancer: long-term survival analysis of the DESTINY-Breast03 trial. Nat Med 2024;30:2208\u20132215."},{"key":"B97","article-title":"Phase III, randomized study of trastuzumab emtansine (T-DM1) {+\/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study","author":"Ellis PA","unstructured":"Ellis PA, Barrios CH, Eiermann W,  Phase III, randomized study of trastuzumab emtansine (T-DM1) {+\/-} pertuzumab (P) vs trastuzumab + taxane (HT) for first-line treatment of HER2-positive MBC: primary results from the MARIANNE study. Presented as 2015 ASCO Annual Meeting; May 29\u2013June 2, 2015; Chicago, Illinois. Abstract 507."},{"key":"B98","series-title":"N Engl J Med","first-page":"1783","article-title":"Trastuzumab emtansine for HER2-positive advanced breast cancer","volume":"367","author":"Verma S","year":"2012","unstructured":"Verma S, Miles D, Gianni L,  Trastuzumab emtansine for HER2-positive advanced breast cancer. N Engl J Med 2012;367:1783\u20131791."},{"key":"B99","series-title":"N Engl J Med","first-page":"783","article-title":"Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2","volume":"344","author":"Slamon DJ","year":"2001","unstructured":"Slamon DJ, Leyland-Jones B, Shak S,  Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001;344:783\u2013792."},{"key":"B100","series-title":"Cancer","first-page":"965","article-title":"Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study","volume":"110","author":"Burstein HJ","year":"2007","unstructured":"Burstein HJ, Keshaviah A, Baron AD,  Trastuzumab plus vinorelbine or taxane chemotherapy for HER2-overexpressing metastatic breast cancer: the trastuzumab and vinorelbine or taxane study. Cancer 2007;110:965\u2013972."},{"key":"B101","series-title":"J Clin Oncol","first-page":"2786","article-title":"Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer","volume":"24","author":"Robert N","year":"2006","unstructured":"Robert N, Leyland-Jones B, Asmar L,  Randomized phase III study of trastuzumab, paclitaxel, and carboplatin compared with trastuzumab and paclitaxel in women with HER-2-overexpressing metastatic breast cancer. J Clin Oncol 2006;24:2786\u20132792."},{"key":"B102","series-title":"J Clin Oncol","first-page":"1642","article-title":"Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840","volume":"26","author":"Seidman A","year":"2008","unstructured":"Seidman A, Berry DA, Cirrincione C,  Randomized phase III trial of weekly compared with every-3-weeks paclitaxel for metastatic breast cancer, with trastuzumab for all HER-2 overexpressors and random assignment to trastuzumab or not in HER-2 nonoverexpressors: final results of Cancer and Leukemia Group B protocol 9840. J Clin Oncol 2008;26:1642\u20131649."},{"key":"B103","series-title":"J Clin Oncol","first-page":"Abstract 717","article-title":"Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer","volume":"23","author":"Schaller G","year":"2005","unstructured":"Schaller G, Bangemann N, Weber J,  Efficacy and safety of trastuzumab plus capecitabine in a German multicentre phase II study of pre-treated metastatic breast cancer. J Clin Oncol 2005;23(Suppl):Abstract 717."},{"key":"B104","series-title":"Cancer Chemother Pharmacol","first-page":"509","article-title":"A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial","volume":"61","author":"Yamamoto D","year":"2008","unstructured":"Yamamoto D, Iwase S, Kitamura K,  A phase II study of trastuzumab and capecitabine for patients with HER2-overexpressing metastatic breast cancer: Japan Breast Cancer Research Network (JBCRN) 00 Trial. Cancer Chemother Pharmacol 2008;61:509\u2013514."},{"key":"B105","series-title":"J Clin Oncol","first-page":"1215","article-title":"Cardiac dysfunction in the trastuzumab clinical trials experience","volume":"20","author":"Seidman A","year":"2002","unstructured":"Seidman A, Hudis C, Pierri MK,  Cardiac dysfunction in the trastuzumab clinical trials experience. J Clin Oncol 2002;20:1215\u20131221."},{"key":"B106","series-title":"N Engl J Med","first-page":"2733","article-title":"Lapatinib plus capecitabine for HER2-positive advanced breast cancer","volume":"355","author":"Geyer C","year":"2006","unstructured":"Geyer C, Forster J, Lindquist D,  Lapatinib plus capecitabine for HER2-positive advanced breast cancer. N Engl J Med 2006;355:2733\u20132743."},{"key":"B107","series-title":"Oncologist","first-page":"924","article-title":"Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial","volume":"15","author":"Cameron D","year":"2010","unstructured":"Cameron D, Casey M, Oliva C,  Lapatinib plus capecitabine in women with HER-2-positive advanced breast cancer: final survival analysis of a phase III randomized trial. Oncologist 2010;15:924\u2013934."},{"key":"B108","series-title":"J Clin Oncol","first-page":"1124","article-title":"Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer","volume":"28","author":"Blackwell KL","year":"2010","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM,  Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. J Clin Oncol 2010;28:1124\u20131130."},{"key":"B109","series-title":"J Clin Oncol","first-page":"2585","article-title":"Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study","volume":"30","author":"Blackwell KL","year":"2012","unstructured":"Blackwell KL, Burstein HJ, Storniolo AM,  Overall survival benefit with lapatinib in combination with trastuzumab for patients with human epidermal growth factor receptor 2-positive metastatic breast cancer: final results from the EGF104900 Study. J Clin Oncol 2012;30:2585\u20132592."},{"key":"B110","series-title":"J Clin Oncol","first-page":"1081","article-title":"TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases","volume":"37","author":"Freedman RA","year":"2019","unstructured":"Freedman RA, Gelman RS, Anders CK,  TBCRC 022: a phase II trial of neratinib and capecitabine for patients with human epidermal growth factor receptor 2-positive breast cancer and brain metastases. J Clin Oncol 2019;37:1081\u20131089."},{"key":"B111","series-title":"J Clin Oncol","first-page":"Abstract 1002","article-title":"Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial","volume":"37","author":"Saura C","year":"2019","unstructured":"Saura C, Oliveira M, Feng YH,  Neratinib + capecitabine versus lapatinib + capecitabine in patients with HER2+ metastatic breast cancer previously treated with \u2265 2 HER2-directed regimens: Findings from the multinational, randomized, phase III NALA trial. J Clin Oncol 2019;37(Suppl):Abstract 1002."},{"key":"B112","series-title":"J Clin Oncol","first-page":"198","article-title":"Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial","volume":"41","author":"Rugo HS","year":"2023","unstructured":"Rugo HS, Im SA, Cardoso F,  Margetuximab versus trastuzumab in patients with previously treated HER2-positive advanced breast cancer (SOPHIA): final overall survival results from a randomized phase 3 trial. J Clin Oncol 2023;41:198\u2013205."},{"key":"B113","series-title":"JAMA Oncol","first-page":"573","article-title":"Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial","volume":"7","author":"Rugo HS","year":"2021","unstructured":"Rugo HS, Im SA, Cardoso F,  Efficacy of margetuximab vs trastuzumab in patients with pretreated ERBB2-positive advanced breast cancer: a phase 3 randomized clinical trial. JAMA Oncol 2021;7:573\u2013584."},{"key":"B114","series-title":"J Clin Oncol","first-page":"5529","article-title":"Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study","volume":"27","author":"Kaufman B","year":"2009","unstructured":"Kaufman B, Mackey JR, Clemens MR,  Trastuzumab plus anastrozole versus anastrozole alone for the treatment of postmenopausal women with human epidermal growth factor receptor 2-positive, hormone receptor-positive metastatic breast cancer: results from the randomized phase III TAnDEM study. J Clin Oncol 2009;27:5529\u20135537."},{"key":"B115","series-title":"Breast","first-page":"27","article-title":"Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial","volume":"21","author":"Huober J","year":"2012","unstructured":"Huober J, Fasching PA, Barsoum M,  Higher efficacy of letrozole in combination with trastuzumab compared to letrozole monotherapy as first-line treatment in patients with HER2-positive, hormone-receptor-positive metastatic breast cancer - results of the eLEcTRA trial. Breast 2012;21:27\u201333."},{"key":"B116","series-title":"J Clin Oncol","first-page":"5538","article-title":"Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer","volume":"27","author":"Johnston S","year":"2009","unstructured":"Johnston S, Pippen J, Pivot X,  Lapatinib combined with letrozole versus letrozole and placebo as first-line therapy for postmenopausal hormone receptor-positive metastatic breast cancer. J Clin Oncol 2009;27:5538\u20135546."},{"key":"B117","series-title":"J Clin Oncol","first-page":"Abstract 1004","article-title":"Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE","volume":"35","author":"Gradishar WJ","year":"2017","unstructured":"Gradishar WJ, Hegg R, Im S-A,  Phase III study of lapatinib (L) plus trastuzumab (T) and aromatase inhibitor (AI) vs T+AI vs L+AI in postmenopausal women (PMW) with HER2+, HR+ metastatic breast cancer (MBC): ALTERNATIVE. J Clin Oncol 2017;35(Suppl):Abstract 1004."},{"key":"B118","series-title":"J Clin Oncol","first-page":"2826","article-title":"First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial","volume":"36","author":"Rimawi M","year":"2018","unstructured":"Rimawi M, Ferrero JM, de la Haba-Rodriguez J,  First-line trastuzumab plus an aromatase inhibitor, with or without pertuzumab, in human epidermal growth factor receptor 2-positive and hormone receptor-positive metastatic or locally advanced breast cancer (PERTAIN): a randomized, open-label phase II trial. J Clin Oncol 2018;36:2826\u20132835."},{"key":"B119","series-title":"Lancet","first-page":"1817","article-title":"Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial","volume":"396","author":"Cortes J","year":"2020","unstructured":"Cortes J, Cescon DW, Rugo HS,  Pembrolizumab plus chemotherapy versus placebo plus chemotherapy for previously untreated locally recurrent inoperable or metastatic triple-negative breast cancer (KEYNOTE-355): a randomised, placebo-controlled, double-blind, phase 3 clinical trial. Lancet 2020;396:1817\u20131828."},{"key":"B120","series-title":"N Engl J Med","first-page":"217","article-title":"Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer","volume":"387","author":"Cortes J","year":"2022","unstructured":"Cortes J, Rugo HS, Cescon DW,  Pembrolizumab plus chemotherapy in advanced triple-negative breast cancer. N Engl J Med 2022;387:217\u2013226."},{"key":"B121","series-title":"N Engl J Med","first-page":"354","article-title":"Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer","volume":"394","author":"Tolaney SM","year":"2026","unstructured":"Tolaney SM, de Azambuja E, Kalinsky K,  Sacituzumab govitecan plus pembrolizumab for advanced triple-negative breast cancer. N Engl J Med 2026;394:354\u2013366."},{"key":"B122","series-title":"N Engl J Med","first-page":"1912","article-title":"Sacituzumab govitecan in untreated, advanced triple-negative breast cancer","volume":"393","author":"Cortes J","year":"2025","unstructured":"Cortes J, Punie K, Barrios C,  Sacituzumab govitecan in untreated, advanced triple-negative breast cancer. N Engl J Med 2025;393:1912\u20131925."},{"key":"B123","series-title":"J Oncol Pract","first-page":"149","article-title":"Management of chemotherapy-induced alopecia with scalp cooling","volume":"14","author":"Kruse M","year":"2018","unstructured":"Kruse M, Abraham J. Management of chemotherapy-induced alopecia with scalp cooling. J Oncol Pract 2018;14:149\u2013154."},{"key":"B124","series-title":"JAMA","first-page":"596","article-title":"Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial","volume":"317","author":"Nangia J","year":"2017","unstructured":"Nangia J, Wang T, Osborne C,  Effect of a scalp cooling device on alopecia in women undergoing chemotherapy for breast cancer: the SCALP randomized clinical trial. JAMA 2017;317:596\u2013605."},{"key":"B125","series-title":"JAMA","first-page":"606","article-title":"Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer","volume":"317","author":"Rugo HS","year":"2017","unstructured":"Rugo HS, Klein P, Melin SA,  Association between use of a scalp cooling device and alopecia after chemotherapy for breast cancer. JAMA 2017;317:606\u2013614."},{"key":"B126","series-title":"Breast Cancer Res Treat","first-page":"199","article-title":"Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis","volume":"163","author":"Rugo HS","year":"2017","unstructured":"Rugo HS, Melin SA, Voigt J. Scalp cooling with adjuvant\/neoadjuvant chemotherapy for breast cancer and the risk of scalp metastases: systematic review and meta-analysis. Breast Cancer Res Treat 2017;163:199\u2013205."},{"key":"B127","series-title":"Front Oncol","first-page":"733","article-title":"Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast cancer patients: the HOPE study","volume":"9","author":"Kinoshita T","year":"2019","unstructured":"Kinoshita T, Nakayama T, Fukuma E,  Efficacy of scalp cooling in preventing and recovering from chemotherapy-induced alopecia in breast cancer patients: the HOPE study. Front Oncol 2019;9:733."},{"key":"B128","series-title":"Breast","first-page":"1","article-title":"Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline\/taxane-based chemotherapy","volume":"40","author":"Vasconcelos I","year":"2018","unstructured":"Vasconcelos I, Wiesske A, Schoenegg W. Scalp cooling successfully prevents alopecia in breast cancer patients undergoing anthracycline\/taxane-based chemotherapy. Breast 2018;40:1\u20133."},{"key":"B129","series-title":"Pain","first-page":"2461","article-title":"Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis","volume":"155","author":"Seretny M","year":"2014","unstructured":"Seretny M, Currie GL, Sena ES,  Incidence, prevalence, and predictors of chemotherapy-induced peripheral neuropathy: a systematic review and meta-analysis. Pain 2014;155:2461\u20132470."},{"key":"B130","series-title":"J Adv Pract Oncol","first-page":"845","article-title":"The impact of peripheral cooling on chemotherapy-induced peripheral neuropathy: an integrative review","volume":"11","author":"Sphar BG","year":"2020","unstructured":"Sphar BG, Bowe C, Dains JE. The impact of peripheral cooling on chemotherapy-induced peripheral neuropathy: an integrative review. J Adv Pract Oncol 2020;11:845\u2013857."},{"key":"B131","series-title":"J Natl Cancer Inst","first-page":"141","article-title":"Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial","volume":"110","author":"Hanai A","year":"2018","unstructured":"Hanai A, Ishiguro H, Sozu T,  Effects of cryotherapy on objective and subjective symptoms of paclitaxel-induced neuropathy: prospective self-controlled trial. J Natl Cancer Inst 2018;110:141\u2013148."},{"key":"B132","series-title":"JAMA Oncol","first-page":"408","article-title":"Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial","volume":"11","author":"Michel LL","year":"2025","unstructured":"Michel LL, Schwarz D, Romar P,  Efficacy of hand cooling and compression in preventing taxane-induced neuropathy: the POLAR randomized clinical trial. JAMA Oncol 2025;11:408\u2013415."},{"key":"B133","series-title":"J Clin Oncol","first-page":"4216","article-title":"Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer","volume":"19","author":"Perez EA","year":"2001","unstructured":"Perez EA, Vogel CL, Irwin DH,  Multicenter phase II trial of weekly paclitaxel in women with metastatic breast cancer. J Clin Oncol 2001;19:4216\u20134223."},{"key":"B134","series-title":"Am J Clin Oncol","first-page":"38","article-title":"Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial","volume":"14","author":"Gasparini G","year":"1991","unstructured":"Gasparini G, Dal Fior S, Panizzoni GA,  Weekly epirubicin versus doxorubicin as second line therapy in advanced breast cancer. A randomized clinical trial. Am J Clin Oncol 1991;14:38\u201344."},{"key":"B135","series-title":"Ann Oncol","first-page":"440","article-title":"Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer","volume":"15","author":"O\u2019Brien ME","year":"2004","unstructured":"O\u2019Brien ME, Wigler N, Inbar M,  Reduced cardiotoxicity and comparable efficacy in a phase III trial of pegylated liposomal doxorubicin HCl (CAELYX\/Doxil) versus conventional doxorubicin for first-line treatment of metastatic breast cancer. Ann Oncol 2004;15:440\u2013449."},{"key":"B136","series-title":"J Clin Oncol","first-page":"2155","article-title":"Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women","volume":"23","author":"Bajetta E","year":"2005","unstructured":"Bajetta E, Procopio G, Celio L,  Safety and efficacy of two different doses of capecitabine in the treatment of advanced breast cancer in older women. J Clin Oncol 2005;23:2155\u20132161."},{"key":"B137","series-title":"JCO Oncol Adv","first-page":"e2400068","article-title":"Randomized trial of fixed-dose capecitabine compared with standard-dose capecitabine in metastatic breast cancer: X-7\/7 trial","volume":"2","author":"Khan QJ","year":"2025","unstructured":"Khan QJ, Bohnenkamp C, Monson TE,  Randomized trial of fixed-dose capecitabine compared with standard-dose capecitabine in metastatic breast cancer: X-7\/7 trial. JCO Oncol Adv 2025;2:e2400068."},{"key":"B138","series-title":"Oncology (Williston Park)","first-page":"11","article-title":"Gemcitabine as single-agent therapy in the management of advanced breast cancer","volume":"15","author":"Seidman AD","year":"2001","unstructured":"Seidman AD. Gemcitabine as single-agent therapy in the management of advanced breast cancer. Oncology (Williston Park) 2001;15:11\u201314."},{"key":"B139","series-title":"Lancet","first-page":"914","article-title":"Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study","volume":"377","author":"Cortes J","year":"2011","unstructured":"Cortes J, O\u2019Shaughnessy J, Loesch D,  Eribulin monotherapy versus treatment of physician\u2019s choice in patients with metastatic breast cancer (EMBRACE): a phase 3 open-label randomised study. Lancet 2011;377:914\u2013923."},{"key":"B140","series-title":"J Clin Oncol","first-page":"594","article-title":"Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane","volume":"33","author":"Kaufman PA","year":"2015","unstructured":"Kaufman PA, Awada A, Twelves C,  Phase III open-label randomized study of eribulin mesylate versus capecitabine in patients with locally advanced or metastatic breast cancer previously treated with an anthracycline and a taxane. J Clin Oncol 2015;33:594\u2013601."},{"key":"B141","series-title":"Cancer","first-page":"2267","article-title":"Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma","volume":"92","author":"Zelek L","year":"2001","unstructured":"Zelek L, Barthier S, Riofrio M,  Weekly vinorelbine is an effective palliative regimen after failure with anthracyclines and taxanes in metastatic breast carcinoma. Cancer 2001;92:2267\u20132272."},{"key":"B142","series-title":"J Clin Oncol","first-page":"3079","article-title":"Randomized trial of hyperthermia and radiation for superficial tumors","volume":"23","author":"Jones EL","year":"2005","unstructured":"Jones EL, Oleson JR, Prosnitz LR,  Randomized trial of hyperthermia and radiation for superficial tumors. J Clin Oncol 2005;23:3079\u20133085."},{"key":"B143","series-title":"J Clin Oncol","first-page":"7794","article-title":"Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer","volume":"23","author":"Gradishar WJ","year":"2005","unstructured":"Gradishar WJ, Tjulandin S, Davidson N,  Phase III trial of nanoparticle albumin-bound paclitaxel compared with polyethylated castor oil-based paclitaxel in women with breast cancer. J Clin Oncol 2005;23:7794\u20137803."},{"key":"B144","series-title":"J Clin Oncol","first-page":"3611","article-title":"Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer","volume":"27","author":"Gradishar WJ","year":"2009","unstructured":"Gradishar WJ, Krasnojon D, Cheporov S,  Significantly longer progression-free survival with nab-paclitaxel compared with docetaxel as first-line therapy for metastatic breast cancer. J Clin Oncol 2009;27:3611\u20133619."},{"key":"B145","series-title":"J Clin Oncol","first-page":"1146","article-title":"Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group","volume":"14","author":"Bastholt L","year":"1996","unstructured":"Bastholt L, Dalmark M, Gjedde SB,  Dose-response relationship of epirubicin in the treatment of postmenopausal patients with metastatic breast cancer: a randomized study of epirubicin at four different dose levels performed by the Danish Breast Cancer Cooperative Group. J Clin Oncol 1996;14:1146\u20131155."},{"key":"B146","series-title":"J Clin Oncol","first-page":"3415","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy","volume":"25","author":"Roche H","year":"2007","unstructured":"Roche H, Yelle L, Cognetti F,  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, as first-line therapy in patients with metastatic breast cancer previously treated with anthracycline chemotherapy. J Clin Oncol 2007;25:3415\u20133420."},{"key":"B147","series-title":"J Clin Oncol","first-page":"3399","article-title":"Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer","volume":"25","author":"Thomas E","year":"2007","unstructured":"Thomas E, Tabernero J, Fornier M,  Phase II clinical trial of ixabepilone (BMS-247550), an epothilone B analog, in patients with taxane-resistant metastatic breast cancer. J Clin Oncol 2007;25:3399\u20133406."},{"key":"B148","series-title":"J Clin Oncol","first-page":"3407","article-title":"Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine","volume":"25","author":"Perez EA","year":"2007","unstructured":"Perez EA, Lerzo G, Pivot X,  Efficacy and safety of ixabepilone (BMS-247550) in a phase II study of patients with advanced breast cancer resistant to an anthracycline, a taxane, and capecitabine. J Clin Oncol 2007;25:3407\u20133414."},{"key":"B149","series-title":"J Clin Oncol","first-page":"968","article-title":"Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial","volume":"21","author":"Nabholtz JM","year":"2003","unstructured":"Nabholtz JM, Falkson C, Campos D,  Docetaxel and doxorubicin compared with doxorubicin and cyclophosphamide as first-line chemotherapy for metastatic breast cancer: results of a randomized, multicenter, phase III trial. J Clin Oncol 2003;21:968\u2013975."},{"key":"B150","series-title":"J Clin Oncol","first-page":"8322","article-title":"Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01","volume":"23","author":"Langley RE","year":"2005","unstructured":"Langley RE, Carmichael J, Jones AL,  Phase III trial of epirubicin plus paclitaxel compared with epirubicin plus cyclophosphamide as first-line chemotherapy for metastatic breast cancer: United Kingdom National Cancer Research Institute trial AB01. J Clin Oncol 2005;23:8322\u20138330."},{"key":"B151","series-title":"J Clin Oncol","first-page":"2812","article-title":"Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results","volume":"20","author":"O\u2019Shaughnessy J","year":"2002","unstructured":"O\u2019Shaughnessy J, Miles D, Vukelja S,  Superior survival with capecitabine plus docetaxel combination therapy in anthracycline-pretreated patients with advanced breast cancer: phase III trial results. J Clin Oncol 2002;20:2812\u20132823."},{"key":"B152","series-title":"J Clin Oncol","first-page":"3950","article-title":"Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment","volume":"26","author":"Albain KS","year":"2008","unstructured":"Albain KS, Nag SM, Calderillo-Ruiz G,  Gemcitabine plus paclitaxel versus paclitaxel monotherapy in patients with metastatic breast cancer and prior anthracycline treatment. J Clin Oncol 2008;26:3950\u20133957."},{"key":"B153","series-title":"J Clin Oncol","first-page":"4498","article-title":"Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer","volume":"29","author":"Stockler MR","year":"2011","unstructured":"Stockler MR, Harvey VJ, Francis PA,  Capecitabine versus classical cyclophosphamide, methotrexate, and fluorouracil as first-line chemotherapy for advanced breast cancer. J Clin Oncol 2011;29:4498\u20134504."},{"key":"B154","series-title":"J Clin Oncol","first-page":"3840","article-title":"Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer","volume":"32","author":"O\u2019Shaughnessy J","year":"2014","unstructured":"O\u2019Shaughnessy J, Schwartzberg L, Danso MA,  Phase III study of iniparib plus gemcitabine and carboplatin versus gemcitabine and carboplatin in patients with metastatic triple-negative breast cancer. J Clin Oncol 2014;32:3840\u20133847."},{"key":"B155","series-title":"Trials","first-page":"63","article-title":"Phase II\/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine\/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial","volume":"17","author":"Yardley DA","year":"2016","unstructured":"Yardley DA, Brufsky A, Coleman RE,  Phase II\/III weekly nab-paclitaxel plus gemcitabine or carboplatin versus gemcitabine\/carboplatin as first-line treatment of patients with metastatic triple-negative breast cancer (the tnAcity study): study protocol for a randomized controlled trial. Trials 2016;17:63."},{"key":"B156","series-title":"Int J Clin Oncol","first-page":"343","article-title":"Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes","volume":"18","author":"Nelli F","year":"2013","unstructured":"Nelli F, Moscetti L, Natoli G,  Gemcitabine and carboplatin for pretreated metastatic breast cancer: the predictive value of immunohistochemically defined subtypes. Int J Clin Oncol 2013;18:343\u2013349."},{"key":"B157","series-title":"Ann Oncol","first-page":"1763","article-title":"nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial","volume":"29","author":"Yardley DA","year":"2018","unstructured":"Yardley DA, Coleman R, Conte P,  nab-Paclitaxel plus carboplatin or gemcitabine versus gemcitabine plus carboplatin as first-line treatment of patients with triple-negative metastatic breast cancer: results from the tnAcity trial. Ann Oncol 2018;29:1763\u20131770."},{"key":"B158","series-title":"Cancer","first-page":"124","article-title":"A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma","volume":"88","author":"Perez EA","year":"2000","unstructured":"Perez EA, Hillman DW, Stella PJ,  A phase II study of paclitaxel plus carboplatin as first-line chemotherapy for women with metastatic breast carcinoma. Cancer 2000;88:124\u2013131."},{"key":"B159","series-title":"Ann Oncol","first-page":"1517","article-title":"Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group","volume":"15","author":"Fountzilas G","year":"2004","unstructured":"Fountzilas G, Kalofonos HP, Dafni U,  Paclitaxel and epirubicin versus paclitaxel and carboplatin as first-line chemotherapy in patients with advanced breast cancer: a phase III study conducted by the Hellenic Cooperative Oncology Group. Ann Oncol 2004;15:1517\u20131526."},{"key":"B160","series-title":"N Engl J Med","first-page":"2666","article-title":"Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer","volume":"357","author":"Miller K","year":"2007","unstructured":"Miller K, Wang M, Gralow J,  Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N Engl J Med 2007;357:2666\u20132676."},{"key":"B161","series-title":"J Clin Oncol","first-page":"Abstract 1005","article-title":"RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC)","volume":"27","author":"Robert NJ","year":"2009","unstructured":"Robert NJ, Dieras V, Glaspy J,  RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab (B) for first-line treatment of HER2-negative locally recurrent or metastatic breast cancer (MBC). J Clin Oncol 2009;27(Suppl):Abstract 1005."},{"key":"B162","series-title":"J Clin Oncol","first-page":"1252","article-title":"RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer","volume":"29","author":"Robert NJ","year":"2011","unstructured":"Robert NJ, Dieras V, Glaspy J,  RIBBON-1: Randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol 2011;29:1252\u20131260."},{"key":"B163","series-title":"Ann Oncol","first-page":"48","article-title":"Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer","volume":"21","author":"Mavroudis D","year":"2010","unstructured":"Mavroudis D, Papakotoulas P, Ardavanis A,  Randomized phase III trial comparing docetaxel plus epirubicin versus docetaxel plus capecitabine as first-line treatment in women with advanced breast cancer. Ann Oncol 2010;21:48\u201354."},{"key":"B164","series-title":"Clin Cancer Res","first-page":"6113","article-title":"Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients","volume":"23","author":"Sun J","year":"2017","unstructured":"Sun J, Meng H, Yao L,  Germline mutations in cancer susceptibility genes in a large series of unselected breast cancer patients. Clin Cancer Res 2017;23:6113\u20136119."},{"key":"B165","series-title":"N Engl J Med","first-page":"523","article-title":"Olaparib for metastatic breast cancer in patients with a germline BRCA mutation","volume":"377","author":"Robson M","year":"2017","unstructured":"Robson M, Im SA, Senkus E,  Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. N Engl J Med 2017;377:523\u2013533."},{"key":"B166","series-title":"Ann Oncol","first-page":"558","article-title":"OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer","volume":"30","author":"Robson ME","year":"2019","unstructured":"Robson ME, Tung N, Conte P,  OlympiAD final overall survival and tolerability results: olaparib versus chemotherapy treatment of physician\u2019s choice in patients with a germline BRCA mutation and HER2-negative metastatic breast cancer. Ann Oncol 2019;30:558\u2013566."},{"key":"B167","series-title":"N Engl J Med","first-page":"753","article-title":"Talazoparib in patients with advanced breast cancer and a germline BRCA mutation","volume":"379","author":"Litton JK","year":"2018","unstructured":"Litton JK, Rugo HS, Ettl J,  Talazoparib in patients with advanced breast cancer and a germline BRCA mutation. N Engl J Med 2018;379:753\u2013763."},{"key":"B168","series-title":"Nat Med","first-page":"628","article-title":"Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial","volume":"24","author":"Tutt A","year":"2018","unstructured":"Tutt A, Tovey H, Cheang MCU,  Carboplatin in BRCA1\/2-mutated and triple-negative breast cancer BRCAness subgroups: the TNT Trial. Nat Med 2018;24:628\u2013637."},{"key":"B169","series-title":"J Clin Oncol","first-page":"4274","article-title":"TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes","volume":"38","author":"Tung NM","year":"2020","unstructured":"Tung NM, Robson ME, Ventz S,  TBCRC 048: Phase II study of olaparib for metastatic breast cancer and mutations in homologous recombination-related genes. J Clin Oncol 2020;38:4274\u20134282."},{"key":"B170","series-title":"J Clin Oncol","first-page":"653","article-title":"TBCRC 048 (olaparib expanded) expansion cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2","volume":"44","author":"Tung NM","year":"2026","unstructured":"Tung NM, Robson ME, Li T,  TBCRC 048 (olaparib expanded) expansion cohorts: phase II study of olaparib monotherapy for patients with metastatic breast cancer with germline mutations in PALB2 or somatic mutations in BRCA1 or BRCA2. J Clin Oncol 2026;44:653\u2013661."},{"key":"B171","series-title":"Ann Med Surg (Lond)","first-page":"103893","article-title":"A review of NTRK fusions in cancer","volume":"79","author":"Manea CA","year":"2022","unstructured":"Manea CA, Badiu DC, Ploscaru IC,  A review of NTRK fusions in cancer. Ann Med Surg (Lond) 2022;79:103893."},{"key":"B172","series-title":"N Engl J Med","first-page":"731","article-title":"Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon A","year":"2018","unstructured":"Drilon A, Laetsch TW, Kummar S,  Efficacy of larotrectinib in TRK fusion-positive cancers in adults and children. N Engl J Med 2018;378:731\u2013739."},{"key":"B173","series-title":"Ann Oncol","first-page":"ix175","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","volume":"29","author":"Demetri GD","year":"2018","unstructured":"Demetri GD, Paz-Ares L, Farago AF,  Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001. Ann Oncol 2018;29:ix175."},{"key":"B174","series-title":"Nat Med","first-page":"682","article-title":"Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial","volume":"32","author":"Besse B","year":"2026","unstructured":"Besse B, Lin JJ, Bazhenova L,  Repotrectinib in NTRK fusion-positive advanced solid tumors: a phase 1\/2 trial. Nat Med 2026;32:682\u2013689."},{"key":"B175","series-title":"Clin Cancer Res","first-page":"3753","article-title":"FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors","volume":"25","author":"Marcus L","year":"2019","unstructured":"Marcus L, Lemery SJ, Keegan P, Pazdur R. FDA approval summary: pembrolizumab for the treatment of microsatellite instability-high solid tumors. Clin Cancer Res 2019;25:3753\u20133758."},{"key":"B176","series-title":"J Clin Oncol","first-page":"2443","article-title":"Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study","volume":"39","author":"Alva AS","year":"2021","unstructured":"Alva AS, Mangat PK, Garrett-Mayer E,  Pembrolizumab in patients with metastatic breast cancer with high tumor mutational burden: results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study. J Clin Oncol 2021;39:2443\u20132451."},{"key":"B177","series-title":"JAMA Netw Open","first-page":"e2341165","article-title":"Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial","volume":"6","author":"Andr\u00e9 T","year":"2023","unstructured":"Andr\u00e9 T, Berton D, Curigliano G,  Antitumor activity and safety of dostarlimab monotherapy in patients with mismatch repair deficient solid tumors: a nonrandomized controlled trial. JAMA Netw Open 2023;6:e2341165."},{"key":"B178","series-title":"Lancet Oncol","first-page":"1261","article-title":"Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial","volume":"23","author":"Subbiah V","year":"2022","unstructured":"Subbiah V, Wolf J, Konda B,  Tumour-agnostic efficacy and safety of selpercatinib in patients with RET fusion-positive solid tumours other than lung or thyroid tumours (LIBRETTO-001): a phase 1\/2, open-label, basket trial. Lancet Oncol 2022;23:1261\u20131273."},{"key":"B179","series-title":"Clin Cancer Res","first-page":"3573","article-title":"FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors","volume":"29","author":"Duke ES","year":"2023","unstructured":"Duke ES, Bradford D, Marcovitz M,  FDA approval summary: selpercatinib for the treatment of advanced RET fusion-positive solid tumors. Clin Cancer Res 2023;29:3573\u20133578."},{"key":"B180","series-title":"Ann Oncol","first-page":"885","article-title":"Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial","volume":"34","author":"Jhaveri K","year":"2023","unstructured":"Jhaveri K, Eli LD, Wildiers H,  Neratinib + fulvestrant + trastuzumab for HR-positive, HER2-negative, HER2-mutant metastatic breast cancer: outcomes and biomarker analysis from the SUMMIT trial. Ann Oncol 2023;34:885\u2013898."},{"key":"B181","series-title":"Nat Med","first-page":"909","article-title":"Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial","volume":"31","author":"Okines AFC","year":"2025","unstructured":"Okines AFC, Curigliano G, Mizuno N,  Tucatinib and trastuzumab in HER2-mutated metastatic breast cancer: a phase 2 basket trial. Nat Med 2025;31:909\u2013916."},{"key":"B182","series-title":"Clin Cancer Res","first-page":"1258","article-title":"The phase II mutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer","volume":"28","author":"Ma CX","year":"2022","unstructured":"Ma CX, Luo J, Freedman RA,  The phase II mutHER study of neratinib alone and in combination with fulvestrant in HER2-mutated, non-amplified metastatic breast cancer. Clin Cancer Res 2022;28:1258\u20131267."},{"key":"B183","series-title":"Lancet Oncol","first-page":"925","article-title":"Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study","volume":"24","author":"Pant S","year":"2023","unstructured":"Pant S, Schuler M, Iyer G,  Erdafitinib in patients with advanced solid tumours with FGFR alterations (RAGNAR): an international, single-arm, phase 2 study. Lancet Oncol 2023;24:925\u2013935."}],"container-title":["Journal of the National Comprehensive Cancer Network"],"original-title":[],"link":[{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e260033.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e260033.xml","content-type":"text\/html","content-version":"vor","intended-application":"syndication"},{"URL":"https:\/\/jnccn.org\/downloadpdf\/journals\/jnccn\/24\/7\/article-e260033.xml","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,9]],"date-time":"2026-07-09T12:41:30Z","timestamp":1783600890000},"score":1,"resource":{"primary":{"URL":"https:\/\/jnccn.org\/view\/journals\/jnccn\/24\/7\/article-e260033.xml"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,7]]},"references-count":183,"journal-issue":{"issue":"7"},"URL":"https:\/\/doi.org\/10.6004\/jnccn.2026.0033","relation":{},"ISSN":["1540-1405","1540-1413"],"issn-type":[{"value":"1540-1405","type":"print"},{"value":"1540-1413","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,7]]}}}